Clinical laboratories in Donostia, Gasteiz and Bilbao
RPS 131/24Privacy
Combined pathway

Cervical cytology

Examines cervical cells for reactive changes, atypia and intraepithelial lesions; it is not the same as an HPV PCR.

SampleCervical sample collected with a brush or spatula, usually in liquid medium.
FastingNo fasting required.
Indicative turnaroundUsually several working days; longer if additional review is needed.
PathwayCombined pathway
Available atDonostia · Gasteiz · Bilbo

Why it is performed

  • Cervical cancer screening according to age and programme.
  • Assess cellular abnormalities and determine follow-up, HPV testing, colposcopy or biopsy.
  • Monitor previous cervical lesions.
  • Assess specimen adequacy.

How it is performed

A speculum is inserted and cells are collected from the cervix. The laboratory prepares the specimen and a qualified professional examines it microscopically using standardised reporting.

Preparation

  • Where possible avoid vaginal intercourse, tampons, creams, pessaries and douching for 24–48 hours.
  • Preferably avoid heavy menstrual bleeding unless indicated.
  • Report pregnancy, menopause, treatments and previous results.
  • Screening frequency depends on age and history, not automatically yearly.

How Askabide processes it

Combined pathway

Each Askabide has a pathology unit and a collection, identification and management pathway. Cytology preparation and reading are performed in the designated unit or partner laboratory by qualified staff with report traceability.

Part is performed at Askabide and another phase or confirmation is processed externally.

Results and indicative intervals

Intervals vary by method, analyser, reagent, units, age, sex, pregnancy, menstrual-cycle phase and reference population. The valid interval is the one printed on the laboratory report.
Parameter or resultIndicative referenceHow it is interpreted
Satisfactory specimenSufficient material for interpretationThe report may state transformation-zone presence and limitations.
Negative for intraepithelial lesion or malignancyNo precancerous changes identifiedDoes not mean zero risk; screening continues.
ASC-USAtypical squamous cells of undetermined significanceOften requires HPV triage or follow-up according to age and protocol.
LSILLow-grade squamous intraepithelial lesionOften HPV-associated; management depends on age, HPV and history.
HSILHigh-grade squamous intraepithelial lesionRequires specialist assessment without unnecessary delay.
AGCAtypical glandular cellsRequires specific evaluation according to age and context.
Unsatisfactory specimenCannot be safely interpretedUsually requires repeat collection.

Important limitations

  • Normal cytology does not exclude all gynaecological cancers or replace consultation for symptoms.
  • Abnormal cytology does not necessarily mean cancer.
  • HPV testing and cytology answer different questions.
  • Clinical decisions use age, current and previous results, immune status and pregnancy.
This website provides general information about clinical laboratory tests and diagnostic procedures. It does not replace an individual clinical assessment or the interpretation of the report issued by the laboratory.
Published reference values are indicative and may vary according to the method, equipment, units and individual characteristics.